Search

Purpose: To explore the effects of recombinant human growth hormone (r-hGH) on inflammatory mediators, immune cells and prognosis in severe neurosurgical patients. Methods: From August 2020 to June 2021, a total of 236 patients who admitted to the neurosurgical intensive care unit (NSICU) were retrospectively analyzed. The patients were divided into GH group (97 cases) and nGH group (139 cases) according to whether they received r-hGH treatment. Parameters including CD4+ T cell counts, inflammatory mediators and prognosis were recorded and assessed. Results: The results showed that the cure time of pneumonia and intracranial infection in GH group patients was significantly shorter than in the nGH group (24.25 ± 4.89 days and 21.33 ± 1.53 days versus 29.13 ± 7.43 days and 25.17 ± 2.32 days, respectively). However, there was no significant difference in GOS scores between two groups (31.96% ≤ 3 and 68.04% > 3 vs 39.57% ≤ 3 and 60.43% > 3) (P = 0.232). Furthermore, the number of CD4+ T cells and CD8+ T cells in the GH group showed a significant upward trend. Last but not least, significant differences were also observed in IL-6 and IL-10 levels between two groups at days 1, 3, and 7. Conclusion: The application of r-hGH in severe neurosurgical patients was effective in increasing the number of CD4+ T cells, down-regulating inflammatory mediators, shortening the cure time of pneumonia, intracranial infections and urinary tract infections, and improving patients' prognosis. [ABSTRACT FROM AUTHOR]

Introduction This study aimed to examine the correlation between the growth response in prepubertal children with idiopathic growth hormone (GH) deficiency after 1 year of treatment with GH to the initial clinical and biochemical parameters. Additionally, the secretion dynamics of GH was also studied by analyzing the GH stimulation test profiles in relation to the GH treatment response. Methods This retrospective study included 84 prepubertal children (47 males and 37 females) with a definitive diagnosis of GH deficiency. The GH secretory indexes GH max , GH secretion rate, and GH secretion volume were analyzed in relation to the response to recombinant human growth hormone (rhGH) treatment as defined by the index of responsiveness (IoR). Correlation and regression models were used to identify the best clinical and biochemical predictors to rhGH treatment. ResultsIoR was negatively correlated with the age (r=–0.607, p<0.01) and positively with the distance of child's height from its midparental height (MPH) r=0.466 (p<0.01) and pretreatment growth velocity (r=0.247, p<0.05). GH secretory indexes were correlated, and the highest association was observed between GH max and GH secretion volume (r=0.883, p<0.01). Among the GH secretory indexes, GH max was the best predictor of IoR (β coef. = –0.514, p<0.001) followed by the GH secretion volume (β coef. = –0.47, p<0.001) and GH secretion rate (β coef. = –0.367 p<0.001). Conclusions The age and the distance of child's height from its MPH are major predictors of GH treatment response in children with idiopathic GH deficiency. The calculation of the other GH secretory indexes GHSR and GHSV are not better predictors of response to GH than GH max. The combination of clinical and biochemical indexes may improve the pretreatment assessment of response to rhGH treatment. [ABSTRACT FROM AUTHOR]

Context.--PIT1 and SF1-multilineage pituitary neuroendocrine tumors (PitNETs) have been defined since the classifi- cation of adenohypophysial tumors based on the PIT1, SF1, and TPIT transcription factors. Objective.--To describe the clinicopathologic features of PIT1 and SF1-multilineage PitNETs and to contribute to the pituitary pathology practice by questioning the expression of NKX2.2 in PitNETs. Design.--We reviewed 345 PitNETs and described the clinicopathologic features of 8 PIT1 and SF1-multilineage tumors. NKX2.2 positivity and staining pattern were compared to those of 45 PitNETs from the control group. Results.--PIT1 and SF1-multilineage PitNET patients had a mean age of 41.13 (range, 14--58 years) and a mean tumor diameter of 14.0 mm (range, 8--20 mm). The most common clinical presentation was acromegaly (6 of 8), and postoperative remission was achieved in all patients. On histomorphologic examination, a pseudopapillary pattern was seen in 5 of the tumors, either focally or diffusely. In addition to PIT1 and SF1, there was a diffuse staining with growth hormone and a predominantly perinuclear staining with cytokeratin 18. With NKX2.2, all multilineage tumors were positive, of which 5 were diffuse and 3 were focal. In the control group, 8 tumors (8 of 45) were positive, of which only 1 was diffuse and 7 were focal. Conclusions.--In conclusion, NKX2.2 is a transcription factor that can be used as an additional tool in pituitary pathology, and PIT1 and SF1-multilineage PitNETs are specific tumors that usually present with acromegaly, show signs of a nonaggressive clinical course, have a pseudopapillary histomorphology, and express NKX2.2. [ABSTRACT FROM AUTHOR]

Objectives: This study is designed in order to compare the efficacy and safety of recombinant human growth hormone (rhGH) with the reference brand. Methods: According to the inclusion criteria, 85 people in 13 Iranian centers were randomly selected to receive biosimilar Somatropin (Somatin®) (44 people) and reference Somatropin (Norditropin®) (41 people) at a dose of 35 µg/kg/d, seven days/week for 12 months. The primary outcomes included height velocity (HV) was measured during 12 months of treatment. Results: The two intervention groups' Height changes were similar. The mean HV was 10.96 cm/year in the biosimilar group and 10.05 cm/year in the reference groups after 12 months. Estimates of the lower bounds of 95% CI for mean height differences in the biosimilar intervention group compared to the reference intervention group did not exceed the 2 cm margin. Therefore, the non-inferiority of biosimilar intervention compared to the brand product is verified. Common ADRs in both groups were nausea in two patients (2.4%), diarrhea in two patients (2.4%), increased body temperature in one patient (1.2%), and headache in one patient (1.2%). Conclusions: The finding of this study indicated that Somatin® and Norditropin® have comparable efficacy and safety profiles. Clinical trial registration: . [ABSTRACT FROM AUTHOR]

The article "Sex Difference in Paediatric Growth Hormone Deficiency: Fact or Fiction?" published in Clinical Endocrinology explores biases impacting the diagnosis of growth hormone deficiency (GHD) in children, particularly the historically reported male predominance. The text discusses various factors contributing to this bias, such as societal perceptions, familial concerns, and provider referrals. It also highlights the need for accurate assessment of GHD frequencies in males and females, suggesting changes in diagnostic criteria and medical practices to address inequities in access to care. The authors emphasize the importance of multi-center studies and medical education campaigns to achieve improved health equity in managing children with short stature. [Extracted from the article]

Traditional methods of protein immobilization often result in activity loss due to random coupling. This study introduces SpyFixer, a variant of SpyCatcher that achieves over 99% efficient site-specific protein immobilization. We applied SpyFixer on two platforms: bio-layer interferometry (BLI) for protein-protein interaction analysis and epoxy agarose resin for antibody purification. Using human growth hormone (hGH) and the Z domain of Protein A as model proteins, we demonstrated that SpyFixer enables efficient, site-specific immobilization on BLI sensors, yielding reproducible kinetic data with lower variability than conventional methods. Additionally, we developed a cost-effective strategy for antibody purification utilizing SpyFixer-modified resin, which exhibited remarkable capture efficiencies exceeding 90%, elution efficiencies over 70%, and purities over 90% for human immunoglobulin G (hIgG) from complex samples, including bacterial lysates, human serum, and recombinant fermentation broth. The resin's loading capacity surpassed 200 mg/mL, and no significant activity loss was observed after 20 regeneration cycles. This study further advances the potential of Spy chemistry in biotechnological applications. [ABSTRACT FROM AUTHOR]